Last 14 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | — | — | 0.05 | — | — | — | — | 3.89 | 2.81 | 2.66 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.09 | 0.07 | 0.00 | 0.02 | 0.15 | 0.06 | 0.17 | 0.19 | 0.28 | 0.49 | 0.78 | — | — |
| — | +11.4% | -99.8% | -88.4% | -44.4% | -87.7% | -78.6% | — | — | — | — | — | — | |
| P/B Ratio | 0.00 | 0.04 | 0.00 | 0.02 | 0.30 | 0.09 | 0.26 | 0.26 | 0.44 | 0.80 | 1.50 | — | — |
| — | -50.6% | -99.9% | -92.5% | -32.3% | -89.3% | -82.5% | — | — | — | — | — | — | |
| P/FCF | — | — | 0.00 | — | — | — | 0.65 | — | 1.11 | — | 18.89 | — | — |
| — | — | -99.8% | — | — | — | -96.6% | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | 2.17 | — | 1.43 | 2.56 | 1.09 | — | — |
| — | — | — | — | — | — | +98.6% | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | -1.16 | — | — | 2.64 | — | 1.26 | 2.58 | 1.12 | — | — |
| — | — | — | — | — | — | +136.2% | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Universe Pharmaceuticals Inc.'s operating margin was -6.8% in Q4 2025, up 18.7 pp QoQ and up 19.8 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -26.9% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 22.7% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.3% | 36.0% | 34.6% | 27.9% | 25.2% | 29.4% | 32.6% | 50.5% | 56.3% | 56.0% | 48.9% | 45.9% | 45.9% |
| — | +22.7% | +6.2% | -44.8% | -55.3% | -47.6% | -33.3% | +10.1% | +22.7% | +38.8% | +3.9% | — | — | |
| Operating Margin | -16.3% | -6.8% | -25.4% | -61.9% | -13.5% | -26.6% | 0.8% | -63.6% | 11.2% | 16.9% | 39.4% | 33.7% | 33.7% |
| — | +74.5% | -3245.4% | +2.6% | -221.0% | -257.0% | -98.0% | -288.7% | -66.9% | -42.4% | +16.5% | — | — | |
| Net Margin | -20.6% | -4.4% | -35.9% | 43.1% | -101.7% | -39.4% | -3.9% | -65.7% | 7.2% | 17.6% | 29.4% | 24.6% | 24.6% |
| — | +88.7% | -826.4% | +165.7% | -1521.1% | -323.5% | -113.2% | -366.8% | -70.9% | -22.5% | +10.3% | — | — |
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.2% | -0.7% | -6.5% | 12.1% | -39.5% | -12.6% | -1.5% | -19.5% | 2.9% | 7.6% | 20.0% | 19.7% | 25.3% |
| — | +94.5% | -326.7% | +162.2% | -1470.9% | -265.2% | -107.6% | -198.5% | -88.6% | -77.8% | -49.1% | — | — | |
| ROA | -5.4% | -0.5% | -4.4% | 7.5% | -25.5% | -8.8% | -1.1% | -16.0% | 2.4% | 6.1% | 14.9% | 13.6% | 16.9% |
| — | +94.1% | -301.3% | +146.6% | -1142.3% | -245.1% | -107.4% | -217.6% | -85.6% | -63.1% | +9.9% | — | — | |
| ROIC | -7.8% | -1.9% | -8.8% | -19.5% | -4.1% | -7.1% | 0.3% | -15.8% | 3.8% | 8.3% | 46.6% | 35.9% | 38.9% |
| — | +73.7% | -3360.8% | -22.9% | -207.0% | -185.4% | -99.4% | -144.1% | -90.2% | -79.8% | -21.3% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 52.0% YoY to 4.07x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.14 | 0.18 | 0.24 | 0.14 | 0.09 | 0.08 | 0.07 | 0.07 | 0.05 | 0.13 | 0.15 |
| — | +18.9% | +61.9% | +107.3% | +237.5% | +88.6% | +59.8% | -33.4% | -50.4% | -63.9% | -80.0% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | 10.02 | — | 1.47 | 1.03 | 0.28 | 0.49 | 0.47 |
| — | — | — | — | — | — | +3485.7% | — | +212.1% | +107.6% | -46.1% | — | — | |
| Current Ratio | 4.07 | 4.07 | 2.78 | 2.54 | 1.63 | 2.68 | 2.26 | 3.17 | 5.06 | 4.50 | 3.73 | 2.91 | 2.29 |
| — | +52.0% | +22.9% | -19.8% | -67.9% | -40.6% | -39.4% | +8.9% | +121.0% | +100.8% | +212.3% | — | — | |
| Quick Ratio | 3.90 | 3.90 | 2.60 | 2.46 | 1.44 | 2.43 | 2.14 | 3.00 | 4.73 | 4.28 | 3.43 | 2.67 | 1.75 |
| — | +60.4% | +21.6% | -18.1% | -69.5% | -43.2% | -37.7% | +12.3% | +169.7% | +142.9% | +356.2% | — | — | |
| Interest Coverage | -14.83 | -2.75 | -24.51 | 31.49 | -90.03 | -49.35 | 4.47 | -152.12 | 38.45 | 76.00 | 205.15 | 82.61 | 82.61 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UPC stock.
Universe Pharmaceuticals Inc.'s current P/E is -0.0x. The average P/E over the last 1 quarters is 0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Universe Pharmaceuticals Inc.'s current operating margin is -16.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Universe Pharmaceuticals Inc.'s business trajectory between earnings reports.